Abstract

International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress var callbackToken='475A017D7E01356'; Skip to main page content HOME CURRENT ISSUE ARCHIVE FEEDBACK SUBSCRIPTIONS ALERTS HELP Keywords GO Advanced » Institution: DeepDyve Sign In as Member / Individual User Name Password Sign In International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress D. F. Woodward , R. L. Jones and S. Narumiya Department of Biological Sciences, Allergan Inc., Irvine, California (D.F.W.); Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, Scotland, United Kingdom (R.L.J.); and Department of Pharmacology, Kyoto University Faculty of Medicine, Yoshida, Kyoto, Japan (S.N.) <h3>Address correspondence to:</h3> Dr. David F. Woodward, Dept. of Biological Sciences RD3–2B, Allergan, Inc., 2525 Dupont Dr., Irvine, CA 92612. E-mail: woodward_david@allergan.com <h2>Abstract</h2> It is now more than 15 years since the molecular structures of the major prostanoid receptors were elucidated. Since then, substantial progress has been achieved with respect to distribution and function, signal transduction mechanisms, and the design of agonists and antagonists ( http://www.iuphar-db.org/DATABASE/FamilyIntroductionForward?familyId=58 ). This review systematically details these advances. More recent developments in prostanoid receptor research are included. The DP 2